Patent · US Active

Fused pentacyclic imidazole derivatives as modulators of TNF activity

US10654861B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

UCB BIOPHARMA SRL · BE

Inventors

Michael Deligny · Brussels, BE
Jag Paul Heer · Brussels, BE
Jean Keyaerts · Brussels, BE
Luce Lépissier · Montréal, CA
Martin Alexander Lowe · Slough, GB

Key dates

Filing date	Mar 31, 2017
Grant date	May 19, 2020
Priority date	—
Expiry date	Mar 31, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.